Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy

Despite promising preclinical results, average response rates to anti-VEGF therapies, such as bevacizumab, are reduced for most cancers, while incurring in remarkable costs and side effects. Currently, there are no biomarkers available to select patients that can benefit from this therapy. Depending...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Commun Biol
Main Authors: Rebelo de Almeida, Cátia, Mendes, Raquel Valente, Pezzarossa, Anna, Gago, Joaquim, Carvalho, Carlos, Alves, António, Nunes, Vitor, Brito, Maria José, Cardoso, Maria João, Ribeiro, Joana, Cardoso, Fátima, Ferreira, Miguel Godinho, Fior, Rita
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7286887/
https://ncbi.nlm.nih.gov/pubmed/32523131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s42003-020-1015-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares